Biostock I am of the uniformed opinion that there is a difference between seeking approval for a new oncology drug, that is one that aims to cure cancer, for example, compared to a drug that seeks to IMPROVE the performance of already APPROVED oncology drugs.
I take the view that the probability of success (approval) is far greater for a drug that IMPROVES the performance of an EXISTING APPROVED DRUG to the probability of success for the original drug.
In the case of AZD0466 then my view is we have a greater chance of approval than AZ had when seeking approval of the original drug.
Perhaps if your opinion of the probability of success for Starpharma in the oncology space is based on approvals for new "cure cancer drugs" you may want to revisit it and consider the probability of success for drugs that aim ONLY to IMPROVE the performance of already approved drugs.
Maybe you have some objective data to inform us in this?
Biostock I am of the uniformed opinion that there is a...
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $55.62M | |||
| Open | High | Low | Value | Volume |
| 14.0¢ | 14.0¢ | 13.5¢ | $3.441K | 25.11K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 381326 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 34884 | 1 |
View Market Depth
| Last trade - 15.46pm 29/04/2024 (20 minute delay) ? |
|
|||||
|
Last
13.0¢ |
Change
0.000 ( 3.70 %) |
||||
| Open | High | Low | Volume | ||
| 13.5¢ | 13.5¢ | 13.0¢ | 5637 | ||
| Last updated 14.53pm 29/04/2024 ? | |||||
| SPL (ASX) Chart |